ACIU CEO Pfeifer Sells 20K Shares at $3.14 on April 15, 2026

When a company’s CEO starts selling shares, investors pay attention. Insider selling can signal confidence issues or portfolio rebalancing. On April 15, 2026, Andrea Pfeifer, Chief Executive Officer of ACIU (AC Immune S.A.), disposed of 20,000 shares at $3.14 per share. This insider transaction totaled approximately $31,425. The filings were disclosed on April 16, 2026. Understanding what this insider selling means requires looking at the details of both transactions and the company’s current position.

CEO Andrea Pfeifer’s Insider Selling Activity

Andrea Pfeifer, serving as Director and Chief Executive Officer of AC Immune S.A., executed two separate insider transactions on April 15, 2026. Both transactions involved the disposition of company shares. The combined activity resulted in the sale of 20,000 shares at an average price of $3.14 per share.

Transaction Details and Filing Information

The first transaction was filed on April 16, 2026 at 11:10 AM UTC. This SEC filing documented a purchase-type transaction (Form 4) involving 10,000 shares. The second transaction was filed later that same day at 12:39 PM UTC. This amended filing (Form 4/A) also involved 10,000 shares sold at the same price. Both filings show Pfeifer retained 3.83 million shares after the transactions.

Understanding the Transaction Codes

The SEC uses specific codes to classify insider trades. The first filing shows “P-Purchase” as the transaction type, while the second shows “S-Sale.” Both are marked as “D” for Disposition, meaning shares were sold or removed from Pfeifer’s holdings. This dual-filing approach ensures complete transparency in insider trading disclosures.

What This Insider Selling Means for ACIU

Insider selling by a CEO can carry multiple interpretations. It does not automatically signal trouble. Executives often sell shares for personal financial planning, tax management, or portfolio diversification. However, the timing and volume matter to investors watching the stock.

CEO Confidence and Market Signals

Pfeifer’s sale of 20,000 shares represents a modest portion of her 3.83 million share holdings. She retained approximately 99.5% of her position. This suggests the sale was likely for personal reasons rather than a loss of confidence in the company. The price of $3.14 per share reflects current market conditions for AC Immune stock.

AC Immune’s Current Market Position

AC Immune S.A. carries a market capitalization of $312.4 million. Meyka AI rates the company with a Grade B, indicating solid fundamentals relative to sector peers and the broader market. The insider selling activity, while notable, does not change the company’s underlying business metrics or strategic direction.

SEC Filings and Insider Trading Transparency

The Securities and Exchange Commission requires all insider transactions to be disclosed within two business days. These filings provide investors with critical information about executive confidence and trading patterns. AC Immune’s filings demonstrate the company’s compliance with SEC regulations.

Form 4 and Form 4/A Explained

Form 4 is the standard SEC form for reporting insider transactions. Form 4/A is an amended version filed when corrections or additional details are needed. In this case, Pfeifer’s transactions generated both a standard Form 4 and an amended Form 4/A on the same day. This is common when multiple transactions occur and require separate documentation for clarity.

Why Investors Monitor Insider Trades

Insider trading data helps investors understand how company leaders view their own stock. When insiders buy, it often signals confidence. When they sell, context matters. Pfeifer’s sale of 20,000 shares at $3.14 should be evaluated alongside her substantial remaining stake and the company’s financial performance.

Key Takeaways for AC Immune Investors

The April 15, 2026 insider transactions by CEO Andrea Pfeifer represent routine executive trading activity. The combined sale of 20,000 shares for approximately $31,425 is modest relative to her total holdings. Pfeifer retained 3.83 million shares, demonstrating continued significant ownership in the company.

What This Means Going Forward

Investors should monitor future insider trading activity to identify patterns. A single transaction rarely signals major changes. However, repeated large sales by multiple executives could indicate shifting sentiment. For now, Pfeifer’s transaction appears consistent with normal portfolio management. The SEC filings provide full transparency into the timing, price, and volume of the trade.

Final Thoughts

Andrea Pfeifer, CEO of AC Immune S.A., sold 20,000 shares at $3.14 per share on April 15, 2026, generating approximately $31,425 in proceeds. The transactions were disclosed via SEC Form 4 and Form 4/A filings on April 16, 2026. Pfeifer retained 3.83 million shares after the sale, indicating continued strong ownership. While insider selling warrants attention, the modest volume and Pfeifer’s substantial remaining stake suggest routine portfolio management rather than loss of confidence. Investors should continue monitoring insider activity alongside AC Immune’s financial performance and market position.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.